📢 Ask Dr. Bikman’s Digital Mind (multilingual):https://benbikman.com/ben-bikmans-digital-ai-mind📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.comTopic:Tirzepatide activates both GLP-1 and GIP receptors, producing weight loss primarily through appetite suppression, slower gastric emptying, reduced cravings, and improved insulin sensitivity—not by forcing the pancreas to make more insulin. Dr. Bikman argues that its best use may be as a temporary tool to help people regain control of food choices and lower the insulin-driving habits that caused metabolic dysfunction.Summary:In this mini-lecture, Dr. Bikman explains tirzepatide, the dual-incretin drug that activates both GLP-1 and GIP receptors. While it is often described as a drug that improves glucose by increasing insulin, Dr. Bikman argues that this explanation misses the bigger metabolic picture.He begins by reviewing the incretin effect, where oral glucose produces a stronger insulin response than the same glucose given intravenously because the gut releases hormones such as GLP-1 and GIP. GLP-1 reduces appetite, slows gastric emptying, suppresses glucagon, and helps regulate glucose, while GIP has traditionally been viewed as more fat-storing because of its actions on fat cells.Ben then resolves the “GIP paradox”: blocking GIP can cause weight loss in animals, yet activating GIP through tirzepatide also causes weight loss. The key, he argues, is insulin. GIP can amplify fat storage only when insulin is elevated, but tirzepatide lowers fasting insulin, reduces meal-related insulin demand, and reduces cravings for foods that drive insulin high. In that lower-insulin context, GIP may support healthier fat tissue function, improve adiponectin, reduce adipose hypoxia, and allow higher GLP-1 activity with better tolerability.The practical takeaway is that tirzepatide should not be viewed as a magic weight-loss injection or a permanent substitute for lifestyle change. Used wisely, it may serve as a temporary tool to reduce carbohydrate cravings, improve satiety, lower insulin demand, and help people relearn healthier eating patterns.References:For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.comNOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related